Download MendeleyBiochemical and structural characterization of meningococcal methylenetetrahydrofolate reductase.
Pantong, W., Pederick, J.L., Maenpuen, S., Tinikul, R., Jayapalan, J.J., Jovcevski, B., Wegener, K.L., Bruning, J.B., Salaemae, W.(2023) Protein Sci 32: e4654-e4654
- PubMed: 37165541
- DOI: https://doi.org/10.1002/pro.4654
- Primary Citation of Related Structures:
7RML - PubMed Abstract:
Methylenetetrahydrofolate reductase (MTHFR) is a key metabolic enzyme in colonization and virulence of Neisseria meningitidis, a causative agent of meningococcal diseases. Here, the biochemical and structural properties of MTHFR from a virulent strain of N. meningitidis serogroup B (NmMTHFR) were characterized. Unlike other orthologs, NmMTHFR functions as a unique homohexamer, composed of three homo-dimerization partners, as shown in our 2.7 Å resolution crystal structure. Six active sites were formed solely within monomers and located away from the oligomerization interfaces. Flavin adenine dinucleotide cofactor formed hydrogen bonds with conserved sidechains, positioning its isoalloxazine ring adjacent to the overlapping binding sites of nicotinamide adenine dinucleotide (NADH) coenzyme and CH 2 -H 4 folate substrate. NmMTHFR utilized NADH (K m = 44 μM) as an electron donor in the NAD(P)H-CH 2 -H 4 folate oxidoreductase assay, but not nicotinamide adenine dinucleotide phosphate (NADPH) which is the donor required in human MTHFR. In silico analysis and mutagenesis studies highlighted the significant difference in orientation of helix α7A (Phe215-Thr225) with that in the human enzyme. The extended sidechain of Met221 on helix α7A plays a role in stabilizing the folded structure of NADH in the hydrophobic box. This supports the NADH specificity by restricting the phosphate group of NADPH that causes steric clashes with Glu26. The movement of Met221 sidechain allows the CH 2 -H 4 folate substrate to bind. The unique topology of its NADH and CH 2 -H 4 folate binding pockets makes NmMTHFR a promising drug target for the development of new antimicrobial agents that may possess reduced off-target side effects.
Organizational Affiliation:
Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Songkhla, Thailand.
